Ex) Article Title, Author, Keywords
Ex) Article Title, Author, Keywords
2019; 11(2): 96-101
Published online September 30, 2019
Copyright © Korean Society for Pharmacoepidemiology and Risk Management.
So Hyun Park,BS1, Seol Hee Park,BS1, Eun Jeong Shin,MS1, Sung Hwan Kim,BS1, Sung Yun Suh,MS1, Yun Hee Jo, PhD1, Yoon Sook Cho,MS1, Seock-Ah Im, MD, PhD2,3,4 and Ju-Yeun Lee, PhD5
박소현1, 박설희1, 신은정1, 김성환1, 서성연1, 조윤희1, 조윤숙1, 임석아2,3,4, 이주연5
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective: Although the combination of trastuzumab with pertuzumab showed better therapeutic efficacy, the adverse events
were relatively higher than trastuzumab monotherapy. We aimed to identify the incidence and pharmacological management
pattern of the pertuzumab induced diarrhea in a real-world clinical practice. Methods: This retrospective study included 178
patients diagnosed with HER2-positive breast cancer and treated with either docetaxel, trastuzumab (control group, n=92) or
docetaxel, trastuzumab, pertuzumab (±carboplatin) (pertuzumab group, n=86) as neoadjuvant or metastatic treatment between
2014 and 2017 at Seoul National University Hospital. The primary outcome was the incidence of pertuzumab induced diar
rhea compared with control group. Results: The incidence of diarrhea in the pertuzumab group was significantly higher than
the control group (75.6% vs. 16.3%, p＜0.001). Pertuzumab induced diarrhea occurred more frequently in the first cycle
than the other cycles. Antidiarrheal medications, mostly loperamide, were prescribed in 62.8% (54/86) of patients and
26.4% (151/573) of cycles with pertuzumab. The prevalence of preemptive prescription of antidiarrheals in the first cycle
was relatively low. In multivariate analysis, we could not find associated factors with pertuzumab induced diarrhea other
than chemotherapy cycle administered. Conclusion: This study showed that the incidence of diarrhea in pertuzumab group
were significantly higher than control group, especially in the first cycle, in real world practice. When treating breast can
cer patients with pertuzumab, awareness of diarrhea and careful management plan is needed. (JPERM 2019;11:96-101)
: Adverse events; Breast cancer; Diarrhea; Incidence; Pertuzumab
Keywords Adverse events, Breast cancer, Diarrhea, Incidence, Pertuzumab
